1	On	nicron B.1.1.529 variant infections associated with severe disease are uncommon in a
2	СО	VID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi
3		
4	Up	endo L. Mseka ^{1,2†} , Jonathan Mandolo ^{1†} , Kenneth Nyoni ^{2†} , Oscar Divala ² , Dzinkambani Kambalame ² ,
5	Dai	niel Mapemba ² , Moses Kamzati ² , Innocent Chibwe ² , Marc Y. R. Henrion ^{1,3} , Kingsley Manda ⁴ , Deus
6	Thi	ndwa ¹ , Memory Mvula ¹ , Bright Odala ² , Raphael Kamng'ona ¹ , Nelson Dzinza ⁴ , Khuzwayo C. Jere ^{1,5,10} ,
7	Nic	holas Feasey ^{1,3} , Antonia Ho ⁶ , Abena S. Amoah ^{7,8} , Melita Gordon ^{1,5} , Todd D Swarthout ⁹ , Amelia
8	Cra	mpin ^{6,7,8} , Robert S. Heyderman ⁹ , Matthew Kagoli ² , Evelyn Chitsa-Banda ² , Collins Mitambo ² , John
9	Phu	uka ¹⁰ , Benson Chilima ² , Watipaso Kasambara ² , Kondwani C. Jambo ^{1,3,10} *, Annie Chauma-Mwale ² *
10		
11	1.	Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi
12	2.	Public Health Institute of Malawi, Lilongwe, Malawi
13	3.	Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
14	4.	National Statistical Office, Zomba, Malawi
15	5.	Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United
16		Kingdom
17	6.	University of Glasgow, Glasgow, United Kingdom
18	7.	London School of Hygiene and Tropical Medicine, London, United Kingdome
19	8.	Malawi Epidemiology and Intervention Unit, Lilongwe, Malawi
20	9.	NIHR Mucosal Pathogens Research Unit, Research Department of Infection, Division of Infection and
21		Immunity, University College London, London, United Kingdom
22	10.	Kamuzu University of Health Sciences (formerly University of Malawi, College of Medicine) Blantyre,
23		Malawi
24		
25		
26	*Co	orresponding and joint senior authors
27	Em	ail: <u>kjambo@mlw.mw</u> (KCJ) or <u>chaumaannie@gmail.com</u> (AM)
28	† C	ontributed equally to this manuscript
29		
30	Ma	in text: 3311 words
31	Ru	nning title: Omicron-associated severe disease is rare in high seroprevalence settings in Malawi

32 Abstract

Background. The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-33 34 CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including 35 Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends 36 of hospitalisations and deaths are needed to aid locally relevant public health policy decisions. 37 Methods. We conducted a population-based serosurvey from December 27, 2021 to January 17, 2022, 38 in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Primary 39 sampling units (PSU) were selected using probability proportionate to the number of households based 40 on the 2018 national census, followed by second-stage sampling units that were selected from listed 41 households. A random systematic sample of households was selected from each PSU within the 7 districts. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using 42 43 WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked 44 immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including 45 cases, hospitalizations and deaths from April 1, 2021 through April 30, 2022, collected using the routine 46 national COVID-19 reporting system. 47 Results. Serum samples were analysed from 4619 participants (57% female; 65% aged 14 to 50 years), of 48 whom 1018 (22%) had received a COVID-19 vaccine. The overall assay-adjusted seroprevalence was 49 86.3% (95% confidence interval (CI), 85.1% to 87.5%). Seroprevalence was lowest among children <13 50 years of age (66%) and highest among adults 18 to 50 years of age (82%). Seroprevalence was higher 51 among vaccinated compared to unvaccinated participants (96% vs. 77%; risk ratio, 6.65; 95% CI, 4.16 to 52 11.40). Urban residents were more likely to test seropositive than those living in rural settings (91% vs. 53 78%; risk ratio, 2.81; 95% CI, 2.20 to 3.62). National COVID-19 data showed that at least a two-fold 54 reduction in the proportion of hospitalisations and deaths among the reported cases in the fourth wave 55 compared to the third wave (hospitalization, 10.7% (95% CI, 10.2 to 11.3) vs 4.86% (95% CI, 4.52 to 56 5.23), p<0.0001; deaths, 3.48% (95% CI, 3.18 to 3.81) vs 1.15% (95% CI, 1.00 to 1.34), p<0.0001). 57 Conclusion. We report reduction in proportion of hospitalisations and deaths from SARS-CoV-2 58 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2 59 seroprevalence but low COVID-19 vaccination coverage. These findings suggest that COVID-19 60 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to targeted vaccination of at-risk populations. 61

62 Introduction

The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was 63 first reported in South Africa on 25th November 2021. Within approximately 25 days the Omicron variant 64 65 was responsible for over 90% of the new clinical cases in South Africa, compared to 80% with the Delta variant 100 days after its emergence in the same setting ¹. Compared to wild type SARS-CoV-2, the 66 Omicron infection rate was four times higher and the Delta rate was twice as high ². Genomic 67 68 sequencing of the Omicron variant has revealed a wide range of non-synonymous mutations ^{3,4}, with 30 mutations identified within its spike protein that have been linked to its high transmission rate and 69 greater immune evasion of neutralizing antibodies ⁵⁻⁷. Despite the Omicron variant being associated with 70 71 higher transmissibility, coronavirus disease (COVID-19) cases caused by this variant have mostly been less severe than previous variants in both low middle income and high-income settings ^{1,8}. 72 73 The COVID-19 pandemic trajectory in Malawi has mirrored that of South Africa⁸. Post emergence of 74

variants of concern in South Africa, Malawi has experienced three COVID-19 waves, caused by Beta,

76 Delta and Omicron⁸. As of July 2022, the number of reported COVID-19 clinical cases and deaths in

77 Malawi were 86,823 and 2,651, respectively ⁹. However, in the context of a low COVID-19 vaccination

78 coverage (4.5%) in Malawi⁹, data from a serosurvey among blood donors showed very high

r9 seropositivity (>65%) by July 2021¹⁰, suggesting widespread community transmission and a huge under-

80 ascertainment of SARS-CoV-2 infections and possibly deaths. A recent sero-epidemiological study in

81 South Africa found high SARS-CoV-2 seropositivity in COVID-19 unvaccinated (68%) and vaccinated

82 (93%) individuals prior to the onset of the Omicron wave, and this was associated with reduced

83 incidence of COVID-19 hospitalisation, recorded deaths and excess deaths thereafter ¹. Consequentially,

84 South Africa has taken a more pragmatic approach to COVID-19, accepting the limited success in

85 preventing infections and allowing for policy development that is built on minimising severe COVID-19,

86 while balancing the direct and indirect societal effects of COVID-19^{11,12}. However, South Africa is the

87 richest economy on the continent ¹³, had stringent lockdowns and has epidemiological profiles of

88 communicable and non-communicable co-morbidities that differ from elsewhere in the region ^{11,12,14}. To

89 inform public health policy decisions in very low COVID-19 vaccine coverage and resource-constrained

90 countries such as Malawi, further data are urgently needed.

91

We, therefore, undertook a population-based serosurvey in Malawi that was conducted from December
27, 2022 to January 17, 2022, during the Omicron-dominant fourth wave. Furthermore, we link this data

- to the national COVID-19 epidemiologic trends in Malawi, including clinical cases, hospitalizations and
 deaths, from April 1, 2021 through April 30, 2022.
- 96

97 Methods

98 Study design

99 The study used a stratified multistage probability sample design, with strata defined by five health

- zones, primary sampling units (PSU) defined by enumeration areas (EAs) within strata, second-stage
- sampling units defined by households within EAs, and finally eligible persons within households.
- 102 Following a sample size calculation, the intention was to sample 12 of the 29 districts of Malawi but due
- to logistical and operational challenges, only 7 of the 12 districts, namely Kasungu, Dowa, Dedza,
- 104 Lilongwe, Zomba, Machinga, and Blantyre, were included in the study participant recruitment phase
- 105 from 27th December 2021 to 17th January 2022. The 7 districts harbor 45% of the population of Malawi
- 106 (7,911,594 of 17,563,749 persons)¹⁵. The other 5 districts that constitute 13% of the Malawi's
- 107 population (2,221,932 of 17,563,749 persons)¹⁵ were included in an earlier serosurvey. The districts of
- Lilongwe (2,626,901), Zomba (851,737) and Blantyre (1,251,484) have both rural and urban areas, and
- 109 harbor 3 of Malawi's main 4 cities.
- 110

111 Sample size calculation

We assumed 5% prevalence of SARS-CoV-2 antibodies, a margin of error of ±5 %, 95% precision of
 estimates, and a design effect of 1.26. Using the following formula, we calculated a sample size (n) of

- 114 7,744 persons.
- 115

$$n = \frac{DEFF \times Np(1-p)}{d^2 / Z_{1-\alpha/2}^2 \times (N-1) + p \times (1-p)}$$

116 Where;

- 117 Population size (N): 17,563,749
- 118 Hypothesized estimate of the prevalence of SARS-CoV-2 (*p*): 5%±-5

119 Confidence limits as % of 100(absolute +/- %) (d): 5%

120 Design effect (DEFF): 1.26

121

122 Malawi has five health zones in three administrative regions (North, Southeast, Southwest, Central East,

and Central West). Districts were selected across Malawi using simple randomisation within the health

124 zones, choosing 2 districts per health zone, making a total of 10 districts, namely Nkhata Bay, Mzimba

125 North, Kasungu, Dowa, Ntcheu, Dedza, Zomba, Machinga, Nsanje, and Neno. Additionally, the two 126 largest cities of Blantyre and Lilongwe were added, totaling 12 districts. The PSUs were selected with 127 probabilities proportionate to the number of households in the EA based on the 2018 census ¹⁵. The 128 second-stage sampling units were selected from lists of households complied by trained staff for each of 129 the sampled PSUs. Upon completion of the listing process, a random systematic sample of households 130 was selected from each PSU within each health zone to the extent feasible. Within the sampled 131 households, all eligible participants were included in the study sample for data collection. Assuming an average household size of 4.4 from the national census ¹⁵, the estimated households to be recruited was 132 133 1,760. However, for the 7 districts, the expected number of households to be recruited was 1,420 and a 134 total sample size of 6,248 persons.

135

Inclusion criteria included being aged ≥5 years, residing in the sampled household, providing informed
 written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide
 the required samples, and having no recent history of nose bleeding. After the consenting process, a
 standard COVID-19 screening tool was implemented using electronic data capturing (Open Data Kit,
 ODK), including demographic data, socio-economic status, comorbidities, COVID-19 symptoms, and
 COVID-19 vaccination status from each enrolled individual. COVID-19 vaccination status was ascertained
 from all participants using the individual national COVID-19 vaccination card.

143

The National Health Sciences Research Committee (NHSRC) (Protocol #21/02/2671) gave ethical
approval for this work and further authorization was also obtained from the District Health Offices of
the participating districts. Community sensitization within each district was implemented through
community leadership and study staff prior to data collection. All participants provided written informed
consent including assent for children; those who were approached were informed that they were free to
decline participation or withdraw at any time without any negative repercussion.

150

151 Sample collection and processing

152 Peripheral venous blood samples (4ml) were obtained from all enrolled participants. Samples were

153 transported to the district laboratory, where serum was separated by density centrifugation, aliquoted

and kept at 2-8°C for transportation to the main storage facility at the National Public Health Reference

155 Laboratory (NPHRL) repository. Serum was archived at -80° C.

157 Serological analysis

158 SARS-CoV-2 Receptor Binding Domain protein immunoglobulin were measured qualitatively in sera 159 using the WANTAI SARS-CoV-2 total antibody commercial ELISA kit as described previously ¹⁰, following 160 the manufacturer's instructions (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., China; WS-1096). The sensitivity and specificity of the assay as independently validated are 94% [95% Cl 0.91 to 161 162 0.97]) and 100% [95% Cl 0.99 to 1,00]), respectively ¹⁶. The results are expressed as a ratio which is 163 calculated by dividing the optical densities of the test sample by those of assay cutoff (mean OD of three internal negative calibrators + 0.16). Specimens giving a ratio of < 0.9 were reported as negative for this 164 165 assay, a ratio of > 1.1 were reported as positive, and a ratio between 0.9 and 1.1 were reported as 166 borderline. Samples with borderline results were retested using a confirmatory assay described below.

167

168 National COVID-19 data sources

169 Data regarding daily cases, hospitalizations, and deaths were sourced from the Public Health Institute of

170 Malawi (PHIM), from 1st April 2021 through 30th April 2022 ⁹. In brief, the routine national COVID-19

171 reporting system works as follows: data from multiple sources at district level covering a 24-hour period

172 (6am-6am) are sent to national level through the national Public Health Emergency Operations Centre

173 (PHEOC). The data undergoes a triple verification system against three sources, surveillance, laboratory,

and case management, and then released to the public.

175

176 Cases included asymptomatic and symptomatic infections with SARS-CoV-2 confirmed by either a

177 nucleic acid amplification assay or a rapid antigen test. Hospitalizations included admissions for SARS-

178 CoV-2 infection, as well as admissions for other illnesses in which SARS-CoV-2 infection was incidentally

identified on routine screening at the time of admission. Death attributable to COVID-19 was defined as

a death resulting from a clinically compatible illness in a probable or confirmed COVID-19 case unless

181 there is a clear alternative cause of death that was not related to COVID-19 disease (e.g., trauma),

182 according to Malawi national guidelines.

183

184 Statistical methods

185 Statistical analyses were performed using R statistical package (version 4.1.0)¹⁷. Categorical variables

186 were summarized as frequencies and percentages. Seropositivity was calculated as the proportion of

those who tested positive among all those tested. The overall seroprevalence of the SARS-CoV-2

antibodies was adjusted for both the assay's sensitivity (94% [95% Cl 0.91 to 0.97]) and specificity (100%

- 189 $[95\% Cl 0.99 \text{ to } 1,00])^{16}$. The χ^2 test or Fisher's exact test was used to compute the proportions of
- 190 participants by number of COVID-19 vaccine doses received across several variables. A multivariate
- 191 logistic regression model was developed to investigate the factors associated with SARS-CoV-2
- 192 seropositivity. The factors included age, sex, occupational exposure and COVID-19 vaccination, which
- 193 were chosen based on known predictors of seropositivity. A p-value of <0.05 was considered
- 194 statistically significant.
- 195

196 Results

197 Participant demographic and household characteristics

198 We enrolled 4,639 participants from 1,415 households, with 4,619 samples from the participants 199 analysed (Figure 1). This constituted 74% of the target sample of 6,248 persons. The response rate was 200 generally high across all districts however reasons for refusal included cultural and religious beliefs 201 against drawing of blood, mistaking the serosurvey for COVID-19 vaccination programmes, lack of 202 incentive and general fear towards COVID-19 related activities. Demographic and household 203 characteristics, comorbidities, participant-reported HIV status, and COVID-19 vaccination status are 204 shown in **Table 1**. In brief, 60% (2,751/4,619) of the participants were between the ages of 18 to 50 205 years, 57% (2,617/4,619) were female, and 7.8% (361/4619) reportedly had had a chronic illness other

- 206 than HIV infection.
- 207

208 SARS-CoV-2 seroprevalence estimates

Among all participants, the overall assay sensitivity and specificity adjusted seroprevalence was 86.3%
(95% confidence interval (CI), 85.1% to 87.5%). The adjusted seroprevalence was heterogeneous across

- the districts, ranging from 80.4% (95% CI, 75.9% to 84.6%) in Dowa, to 93.7% (95% CI, 91.1% to 96.0%) in
- 212 Blantyre (Table 2).
- 213

Participants residing in urban areas were more likely to test seropositive than those from rural areas (91% vs. 78%; adjusted odds ratio, 2.81; 95% Cl, 2.20 to 3.62) (**Table 3**). Males were less likely to be seropositive than females (78% vs 84%; adjusted odds ratio, 0.61; 95% Cl, 0.52 to 0.72). The seroprevalence among the age groups did not vary greatly among those aged 13 years and above; but it was lowest in children younger than 13 years of age (66%) and highest among adults 18 to 50 years of age (82%). Children 13 to 17 years of age were more likely to be seropositive than children younger than

220 13 years of age (78% vs. 66%; adjusted odds ratio, 1.80; 95% CI, 1.15 to 2.83). Participants who had

- received a COVID-19 vaccine were more likely to be seropositive than unvaccinated participants (1 dose
- vs no dose, 94% vs. 77%; adjusted odds ratio, 4.83; 95% CI, 3.40 to 7.10; 2 doses vs no dose, 97% vs.
- 223 77%; adjusted odds ratio, 6.65; 95% CI, 4.16 to 11.4).
- 224

225 Participants who reported COVID-19 symptoms in the last two weeks, including persistent cough, loss of 226 taste, sore throat, chest pain, myalgia, shortness of breath, severe/unusual headache, fatigue, fever and 227 runny/blocked nose, were more likely to be seropositive than participants who did not report any 228 symptoms (83% vs. 80%; adjusted odds ratio, 1.21; 95% CI, 1.03 to 1.42) (Table 3). Participants who 229 reached secondary (86 % vs. 78 %; adjusted odds ratio, 1.27; 95% CI, 1.02 to 1.59) and tertiary (96 % vs. 230 78 %; adjusted odds ratio, 2.83; 95% CI, 1.49 to 5.99) education levels had a higher seroprevalence than 231 participants at primary education level. Participants with a regular waged job were more likely to be 232 seropositive than unwaged participants (93 % vs. 79 %; adjusted odds ratio, 1.60; 95% CI, 1.02 to 2.61).

233

234 COVID-19 vaccination

- 235 Of the 4,619 participants who were included in the data analysis, 3,794 of them had known age and
- were eligible for COVID-19 vaccination at the time of the study being 18 years and older (**Table 4**).
- 237 Overall, 23% (878/3,794) of the participants had received at least one dose of the COVID-19 vaccine,
- with 12% (458/3,794) receiving 1 dose and 11% (420/3,794) received 2 doses. The age group of 50 years
- and above had a higher proportion of vaccinated individuals than those between 18 to 49 years (33% vs.
- 240 19%, p<0.001). Moreover, the age group of 50 years and above had a higher proportion of vaccinated
- individuals that received 2 doses than those between the ages of 18 to 49 years (19% vs. 8%).

- All major cities of Lilongwe (16%), Blantyre (15%) and Zomba (13%), had a greater proportion of
- individuals that received two doses of COVID-19 vaccine compared to the other districts (all < 9.6%).
- 245 Moreover, the proportion of 2-dose vaccinated individuals was higher in urban areas than rural areas
- 246 (17% vs 14%, p<0.001). A greater proportion of participants who had gone up to tertiary education level
- 247 (28%) received two doses of the COVID-19 vaccine, whereas those at primary and secondary level were
- 248 8% and 14%, respectively (p<0.001). The proportion of 2-dose vaccinated people were higher (p<0.001)
- among those with a regular wage (35%) compared to unwaged (9%) or those with an irregular wage
- 250 (11%).
- 251

252 National COVID-19 epidemiological trends

Our study was conducted during the fourth wave, which was dominated by the Omicron variant ^{18,19}. 253 254 During this wave, the daily case incidence increased more rapidly and also decreased more quickly 255 compared to the third (Delta) wave, with the peak in July 2021 and December 2021, respectively (Figure 256 2). The number of confirmed clinical cases at the peak of the third wave were 13300 and during the 257 fourth wave were 14298, whereas the peak episodes of hospitalization were 1429 and 695, while deaths 258 were 463 and 164, respectively. The proportion of hospitalisation within the confirmed clinical cases was 259 two-fold lower in the fourth wave compared to the third wave (4.86% (95% CI, 4.52 to 5.23) (695/14298) 260 vs 10.7% (95% CI, 10.2 to 11.3) (1429/13330), p<0.0001). While, the proportion of deaths within the confirmed clinical cases was three-fold lower in the fourth wave compared to the third wave (1.15% 261 262 (95% CI, 1.00 to 1.34) (164/14298) vs 3.48% (95% CI, 3.18 to 3.81) (463/13330), p<0.0001).

263

264 Discussion

265 The results of our study showed high SARS-CoV-2 seropositivity of 86% across the population during the 266 Omicron B.1.1.529 variant-dominated fourth wave. This high seroprevalence was primarily due to prior SARS-CoV-2 infection, as evidence by the low vaccine uptake in this population and the 70% 267 268 seroprevalence among participants who had not received a COVID-19 vaccine. Against this background, 269 we observed reduction in the proportion of hospitalization and deaths from the reported infections 270 during the Omicron-dominated fourth wave, compared to the Delta-dominated third wave. This is in 271 support of Madhi et al that have observed a similar phenomenon in South Africa, which they termed "decoupling" 20. 272

273

274 Notwithstanding the reduced number of hospitalization and deaths in Malawi, the Omicron variant drove a rapid rise in SARS-CoV-2 infections consistent with its high transmissibility ^{21,22} as observed in 275 other settings ^{1,23}. Based on previous estimates from our adult blood donor serosurvey, the estimated 276 277 seroprevalence by July 2021 was >65% ¹⁰, reaching around 80% by November 2021 (unpublished), 278 before the Omicron-dominant fourth wave in Malawi. In South Africa, a lower rate of hospitalization and 279 deaths was associated with the high seroprevalence before the onset of the Omicron-dominant wave, driven by both vaccination and infection ¹. In Malawi, there was at least a two-fold reduction in 280 281 proportion of COVID-19 hospitalizations and deaths among the clinical cases reported in the fourth 282 compared to third wave. Madhi et al. suggests that, in South Africa, cell-mediated immunity induced 283 through prior infection and vaccination contributed to protective immunity against severe disease ¹. This

suggestion was based on earlier evidence that showed that the Omicron variant highly evades
 neutralization antibody activity ^{5-7,24} but is ably cross-recognized by T cells ^{25,26}. Evidence of T cell mediated protection against COVID-19 is accumulating and is consistent with their role in viral
 clearance, where they might not directly prevent infection but halt progression of infection to disease
 ^{27,28}.

289

290 The SARS-CoV-2 seroprevalence was generally high across all the seven districts surveyed in the current study, with higher seroprevalence in urban compared to rural areas, as reported in our blood donor 291 serosurvey ¹⁰ and in other sub-Saharan African settings ²⁹. This is consistent with national COVID-19 data 292 293 at the time of the study that reported 51% of confirmed cases in the country were from the cities of 294 Blantyre and Lilongwe ⁹, with a caveat that rural areas had relatively fewer SARS-CoV-2 testing sites. The 295 high seroprevalence seen in the urban areas could be attributed to these areas being hotspots for SARS-296 CoV-2 transmission. Individuals residing in the urban areas were more likely to have attained higher 297 level education and have regular waged jobs, likely increasing their risk of exposure due to increased 298 interaction with others, closed workspaces, frequent travel on public transport and international travel 299 that also increases the risk of exposure to new variants. Supporting this, seroprevalence was higher in 300 those with secondary or tertiary level education, and in those on regular waged jobs. Our study also 301 found men to have a lower seropositivity, which is contrary to male-dominated reported national 302 COVID-19 cases, this could suggest that females experienced less severe forms of COVID-19 to trigger 303 testing or were less likely to present for testing. These findings highlight the need to tailor public health 304 measures according to context as the pandemic progresses.

305

306 Our study has some limitations. First, we used an anti-RBD ELISA assay that was developed against the 307 wild type SARS-CoV-2, hence the extensive mutations in the RBD in the Omicron variant could result in 308 false negative results in individuals who were previously or actively infected with this variant. 309 Nevertheless, considering the extremely high seroprevalence, our conclusions are unlikely to be 310 significantly impacted by the theoretical possibility of lower assay specificity. Second, the use of publicly available reported national COVID-19 surveillance data has its own caveats, including under 311 312 ascertainment of the cases and deaths or changes in testing strategies over time, and this needs to be taken into consideration when interpreting the comparisons across the waves. However, to our 313 314 knowledge, there were no significant changes in the clinical management policy of severe COVID-19 315 cases between the third and fourth waves, hence the comparison between the waves is likely accurate.

Thirdly, we had a relatively small numbers of children to give precise estimates of seroprevalence in this population. Finally, the study was conducted and concluded before the end of the fourth wave, hence this could result in seroprevalence estimates being an underestimate of the actual cumulative exposure for Malawi.

320

321 The reduction in the proportion of hospitalizations and deaths from COVID-19 during the Omicron-322 dominant fourth wave in Malawi, in the context of low vaccination coverage and high infection-induced 323 seroprevalence, could be a watershed moment for the COVID-19 pandemic in under-vaccinated 324 countries like Malawi. However, the number of COVID-19 preventable deaths are still significant and a 325 greater focus on identifying and protecting those most at risk is increasingly important. Up until a 326 sarbecoviruses or pan-coronavirus vaccine is available, to maximise protection against severe disease in 327 high seroprevalence and resource-constrained settings like Malawi, there might be the need to amend 328 vaccination policy of current COVID-19 vaccines from mass vaccination campaigns to targeted 329 vaccination that focuses on at-risk populations including the elderly and those with co-morbidities.

330

331 Acknowledgements

332 The authors thank all participants whose samples are used in this study. We thank all the district teams

and leadership for their support and contribution to this study. We also thank Mtisunge Yelewa,

- 334 Selemani Ngwira, Eranive Chipungu, Triza Chirwa, and Sikhona Chipeta. We acknowledge use of the
- 335 WHO Unity protocols for this study.
- 336

337 Author contributions

- 338 Conceptualization of study: ACM, WK, OD, DK, JP, CM
- 339 Study design: ACM, WK, OD, DK, JP, CM, MK, ND
- 340 Data collection: ULM, DM, KN
- 341 Laboratory testing: JM, MM, IC, BO
- 342 Data analysis: KCJ1, ULM, JM
- 343 Accessed and verified the underlying data: KCJ1, MK
- 344 Study management: ULM, KN
- 345 Initial manuscript draft: ULM, KCJ1, ACM
- 346 Final manuscript writing: ULM, KCJ1, ACM, RSH, TDS, KCJ2, NF, ASA, AC
- 347 Manuscript review and approval: All authors

- 348 Funding
- 349 Supported by the Bill and Melinda Gates Foundation (INV-039481).

350

- 351 Declaration of interest
- 352 All authors declare no conflict of interest.
- 353
- 354 References

1. Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(14): 1314-26.

Araf Y, Akter F, Tang Y-d, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and
 responses to current COVID-19 vaccines. *Journal of Medical Virology* 2022; **94**(5): 1825-32.

Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant
 in southern Africa. *Nature* 2022; **603**(7902): 679-86.

- McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune
 evasion and receptor engagement. *Science* 2022; **375**(6583): 864-8.
- 363 5. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern
 364 Omicron. *Cellular & Molecular Immunology* 2022; **19**(2): 293-5.

365 6. Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM
 366 structure of spike protein–ACE2 complex. *Science* 2022; **375**(6582): 760-4.

367 7. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody 368 mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell* 2022; **185**(3): 447 369 56.e11.

370 8. JHU. COVID-19 Case Tracker 2020. <u>https://coronavirus.jhu.edu/map.html</u>.

- 9. PHIM. Daily COVID-19 Situation Report. Lilongwe: Public Health Institute of Malawi, Ministry of
 Health 2022.
- Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood donors: an
 analysis of seroprevalence and variant dynamics between January 2020 and July 2021. *BMC Med* 2021; **19**(1): 303.
- 376 11. Madhi S, Abdullah F, Myers J. South Africa has changed tack on tackling COVID: why it makes
 377 sense. The Conversation. 2022.

Ueckermann V. What South Africa has learnt about COVID and what the next steps could be. The
 Conversation. 2022 15 February 2022.

- 380 13. Bank TW. GDP per capita. 2022. <u>https://data.worldbank.org</u>.
- 381 14. WHO. Monitoring health for the SDGs, sustainable development goals: WHO, 2022.
- 15. NSO. Malawi Population and Housing Census. Zomba: National Statistical Office, Malawi, 2018.
- 16. Wantai. WANTAI SARS-CoV-2 Ab ELISA 2021. https://www.fda.gov/media/140929/download.
- Team RC. R: A language and environment for statistical computing. 2021. <u>https://www.R-</u>
 <u>project.org/</u>.
- Anscombe C, Lissauer S, Thole H, et al. A comparison of four epidemic waves of COVID-19 in
 Malawi; an observational cohort study. *medRxiv* 2022: 2022.02.17.22269742.

388 19. Chibwana MG, Thole HW, Anscombe C, et al. Differential symptoms among COVID-19 outpatients 389 before and during periods of SARS-CoV-2 Omicron variant dominance in Blantyre, Malawi: a prospective

390 observational study. *medRxiv* 2022: 2022.07.15.22277665.

Madhi SA, Ihekweazu C, Rees H, Pollard AJ. Decoupling of omicron variant infections and severe
 COVID-19. *Lancet* 2022; **399**(10329): 1047-8.

Willett BJ, Grove J, MacLean OA, et al. The hyper-transmissible SARS-CoV-2 Omicron variant
 exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. *medRxiv* 2022:
 2022.01.03.21268111.

Peacock TP, Brown JC, Zhou J, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in
human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. *bioRxiv* 2022:
2021.12.31.474653.

23. Elliott P, Bodinier B, Eales O, et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. *Science* 2022; **375**(6587): 1406-11.

401 24. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing 402 antibodies. *Nature* 2022; **602**(7898): 657-63.

403 25. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize 404 Omicron. *Nature* 2022.

405 26. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is 406 preserved in most but not all individuals. *Cell* 2022; **185**(6): 1041-51.e6.

407 27. Moss P. The T cell immune response against SARS-CoV-2. *Nature Immunology* 2022; 23(2): 186408 93.

Bange EM, Han NA, Wileyto P, et al. CD8(+) T cells contribute to survival in patients with COVID19 and hematologic cancer. *Nat Med* 2021; **27**(7): 1280-9.

411 29. Kleynhans J, Tempia S, Wolter N, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban
412 Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.
413 *Emerg Infect Dis* 2021; **27**(12): 3020-9.

414

415

416

417

418

419

420

421

422

423

424

426 Figure legends

- 427 **Figure 1. Survey participant recruitment**. The survey was conducted between 27th December 2021 to
- 428 17th January 2022. The survey included primary sampling units (PSU), which were selected with
- 429 probabilities proportionate to the number of households based on the 2018 census. The second-stage
- 430 sampling units were selected from lists of households sampled PSUs, then a random systematic sample
- 431 of households was selected from each PSU within each health zone to the extent feasible.

432

433 Figure 2. COVID-19 Cases, Hospitalizations, and Deaths in Malawi, from April 2021 through April 2022.

- 434 Shown are incidences of monthly cases, hospitalizations, and deaths attributable to coronavirus disease
- 435 2019 (COVID-19). The data were sourced from the Public Health Institute of Malawi (PHIM). Cases
- 436 included asymptomatic and symptomatic infections with severe acute respiratory syndrome coronavirus
- 437 2 (SARS-CoV-2) confirmed by either a nucleic acid amplification assay or a rapid antigen test.
- 438 Hospitalizations included admissions for SARS-CoV-2 infection, as well as admissions for other illnesses
- 439 in which SARS-CoV-2 infection was incidentally identified on routine screening at the time of admission.
- 440 Death attributable to COVID-19 was defined as a death resulting from a clinically compatible illness in a
- 441 probable or confirmed COVID-19 case unless there is a clear alternative cause of death that cannot be
- 442 related to COVID disease (e.g., trauma), according to the national guidelines

443

- 445
- 446
- 447
- 448
- 449
- 450
- 451

452 Tables

453 **Table 1. Participant demographics and clinical history**

Characteristic	N = 4,619 ¹
Sex	
Female	2,617 (57%)
Male	2,002 (43%
Age group	
<13 yrs	187 (4.4%)
13 to 17 yrs	230 (5.5%)
18 to 50 yrs	2,751 (65%
>50 yrs	1,043 (25%
Unknown	408
COVID-19 Vaccination state	ls
0 doses	3,606 (78%
1 dose	521 (11%)
2 doses	492 (11%)
SARS-CoV-2 serostatus	
Negative	865 (19%)
Positive	3,754 (81%
Symptoms in the last 2 wee	eks
Yes	1,747 (38%)
No	2,870 (62%
Unknown	2 (<0.1%)
Occupation	
Irregular	522 (11%)
Regular	364 (7.9%)
Unwaged	3,733 (81%
Education level	
Primary	2,086 (45%
Secondary	1,038 (22%
Tertiary	232 (5.0%)
No formal education	1,263 (27%
Comorbidities	,
Yes	361 (7.8%)
No	4,258 (92%
HIV status	.,=== (===
HIV-	4,457 (96%
HIV+	162 (3.5%)
Economic zone	
Urban	1,373 (30%
Rural	1,156 (25%)
*Other	2,090 (45%
Location	2,000 (4070
Blantyre	768 (17%)
Dedza	
	527 (11%)
Dowa	441 (9.5%)
Kasungu	645 (14%)
	1,327 (29%
Lilongwe Machinga	477 (10%)

454

455

* includes other districts apart from city-harboring districts of Lilongwe, Blantyre and Zomba

	n	Seroprevalence	95% Confidence Interval	Seroprevalence *(adjusted)	95% Confidence Interval *(adjusted)
All	3755/4619	81.3%	80.1% to 82.4%	86.5%	83.3% to 89.2%
>13 years	124/188	66.3%	59.1% to 73.0%	70.2%	62.0% to 77.5%
13-17 years	179/230	77.8%	71.9% to 83.0%	82.8%	75.8% to 88.8%
18-50 years	2261/2750	82.2%	80.7% to 83.6%	87.5%	84.1% to 90.5%
>50 years	847/1043	81.2%	78.7% to 83.5%	86.4%	82.3% to 89.9%
Blantyre	678/768	88.3%	85.8% to 90.5%	93.9%	89.7% to 97.5%
Dedza	406/527	77.0%	73.2% to 80.6%	81.9%	76.9% to 86.3%
Dowa	334/441	75.7%	75.7% to 79.7%	80.6%	75.1% to 85.2%
Kasungu	486/645	75.3%	71.8% to 78.6%	80.2%	75.4% to 84.3%
Lilongwe	1132/1327	85.3%	83.3% to 87.2%	90.8%	86.9% to 94.0%
Machinga	380/477	79.7%	75.8% to 83.2%	84.8%	79.6% to 89.2%
Zomba	338/434	77.9%	73.7% to 81.7%	82.9%	77.4% to 87.5%
Urban	1252/1373	91.2%	89.6% to 92.6%	97.0%	93.6% to 99.6%
Rural	896/1156	77.5%	75.0% to 79.9%	82.5%	78.5% to 85.9%

457 Table 2. SARS-CoV-2 antibody seroprevalence estimates

458 * The sensitivity and specificity of the assay as independently validated are 94% [95% Cl 0.91 to 0.97])

459 and 100% [95% Cl 0.99 to 1,00]), respectively

- -

473 Table 3. Factors associated with SARS-CoV-2 antibody seropositivity

	Seropositivity				Univariate				Multivariable		
Characteristic	Overall , N = 4,619 ¹	Negative, N = 865 ⁷	Positive , N = 3,754 ¹	p-value ²	Ν	OR ³	95% CI ³	p-value	OR ³	95% Cl ³	p-valu
Age group				<0.001	4,619						
<13 yrs	187 (100%)	63 (34%)	124 (66%)			_	—		_	—	
13 to 17 yrs	230 (100%)	51 (22%)	179 (78%)			1.78	1.16, 2.76	0.009	1.76	1.13, 2.77	0.013
18 to 50 yrs	2,751 (100%)	490 (18%)	2,261 (82%)			2.34	1.70, 3.21	<0.001	1.68	1.19, 2.35	0.003
>50 yrs	1,043 (100%)	196 (19%)	847 (81%)			2.20	1.56, 3.08	<0.001	1.56	1.08, 2.24	0.017
Unknown						2.68	1.79, 4.02	<0.001	1.82	1.18, 2.80	0.006
Sex				<0.001	4,619						
Female	2,617 (100%)	417 (16%)	2,200 (84%)			_	_		_	_	
Male	2,002 (100%)	448 (22%)	1,554 (78%)			0.66	0.57, 0.76	<0.001	0.61	0.52, 0.72	<0.001
Economic zone				<0.001	4,619						
Rural	1,156 (100%)	260 (22%)	896 (78%)			_	_		_	_	
Urban	1,373 (100%)	121 (8.8%)	1,252 (91%)			3.00	2.39, 3.80	<0.001	2.81	2.20, 3.62	<0.001
*Other	2,090 (100%)	484 (23%)	1,606 (77%)			0.96	0.81, 1.14	0.7	1.00	0.84, 1.20	>0.9
Education level				<0.001	4,619						
Primary	2,086 (100%)	463 (22%)	1,623 (78%)			_	_		_	_	
Secondary	1,038 (100%)	146 (14%)	892 (86%)			1.74	1.43, 2.14	<0.001	1.28	1.02, 1.60	0.032
Tertiary	232 (100%)	10 (4.3%)	222 (96%)			6.33	3.52, 12.9	<0.001	2.84	1.49, 6.00	0.003
No formal education	1,263 (100%)	246 (19%)	1,017 (81%)			1.18	0.99, 1.40	0.062	0.97	0.81, 1.18	0.8
Occupation				<0.001	4,619						
Unwaged	3,733 (100%)	768 (21%)	2,965 (79%)			_	_		_	_	
Irregular	522 (100%)	73 (14%)	449 (86%)			1.59	1.24, 2.08	<0.001	1.14	0.87, 1.52	0.4
Regular	364 (100%)	24 (6.6%)	340 (93%)			3.67	2.46, 5.74	<0.001	1.60	1.02, 2.60	0.051
Any symptoms in the last 2 weeks	6			0.079	4,619						
Yes	1,747 (100%)	304 (17%)	1,443 (83%)			_	_		_	_	
No	2,870 (100%)	560 (20%)	2,310 (80%)			0.87	0.74, 1.01	0.075	0.83	0.70, 0.97	0.024
Unknown	2 (100%)	1 (50%)	1 (50%)			0.21	0.01, 5.34	0.3	0.05	0.00, 1.76	0.071
COVID-19 Vaccination status				<0.001	4,619						
0 doses	3,606 (100%)	816 (23%)	2,790 (77%)			_	_		_	_	
1 dose	521 (100%)	32 (6.1%)	489 (94%)			4.47	3.15, 6.57	<0.001	4.96	3.48, 7.33	<0.001
2 doses	492 (100%)	17 (3.5%)	475 (97%)			8.17	5.17, 13.9	<0.001	6.64	4.16, 11.4	<0.001

 3 OR = Odds Ratio, CI = Confidence Interval

474	
-----	--

475

476


478 Table 4. COVID-19 vaccination

79	Characteristic	Overall , N = 3,794 ¹	0 doses , N = 2,916 ⁷	1 dose , N = 458 ¹	2 doses , N = 420 ⁷	p-value
00	Age group					<0.001
80	18 to 50 yrs	2,751 (100%)	2,216 (81%)	312 (11%)	223 (8.1%)	
81	>50 yrs	1,043 (100%)	700 (67%)	146 (14%)	197 (19%)	
01	Sex					0.011
82	Female	2,176 (100%)	1,689 (78%)	274 (13%)	213 (9.8%)	
	Male	1,618 (100%)	1,227 (76%)	184 (11%)	207 (13%)	
83	HIV status					0.6
	HIV-	3,668 (100%)	2,824 (77%)	441 (12%)	403 (11%)	
84	HIV+	126 (100%)	92 (73%)	17 (13%)	17 (13%)	
	Location					<0.00
35	Blantyre	611 (100%)	476 (78%)	44 (7.2%)	91 (15%)	
	Dedza	468 (100%)	394 (84%)	61 (13%)	13 (2.8%)	
36	Dowa	308 (100%)	208 (68%)	83 (27%)	17 (5.5%)	
37	Kasungu	538 (100%)	382 (71%)	105 (20%)	51 (9.5%)	
,,	Lilongwe	1,124 (100%)	834 (74%)	109 (9.7%)	181 (16%)	
38	Machinga	401 (100%)	364 (91%)	14 (3.5%)	23 (5.7%)	
	Zomba	344 (100%)	258 (75%)	42 (12%)	44 (13%)	
39	Education level					<0.00
	Primary	1,602 (100%)	1,265 (79%)	202 (13%)	135 (8.4%)	
90	Secondary	910 (100%)	685 (75%)	95 (10%)	130 (14%)	
	Tertiary	206 (100%)	128 (62%)	20 (9.7%)	58 (28%)	
91	No formal education	1,076 (100%)	838 (78%)	141 (13%)	97 (9.0%)	
17	Occupation					<0.00
92	Irregular	462 (100%)	368 (80%)	45 (9.7%)	49 (11%)	
)3	Regular	308 (100%)	169 (55%)	31 (10%)	108 (35%)	
	Unwaged	3,024 (100%)	2,379 (79%)	382 (13%)	263 (8.7%)	
94	Economic zone					<0.00
	Urban	1,123 (100%)	855 (76%)	82 (7.3%)	186 (17%)	
95	Rural	956 (100%)	713 (75%)	113 (12%)	130 (14%)	
	*Other	1,715 (100%)	1,348 (79%)	263 (15%)	104 (6.1%)	
96	¹ n (%) ² Pearson's Chi-squared	d test				


497

* includes other districts apart from city-harboring districts of Lilongwe, Blantyre and Zomba

498



523 Figure 2.





- 525
- 526
- 527